Literature DB >> 14999640

False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam.

Claudio Viscoli1, Marco Machetti, Paola Cappellano, Barbara Bucci, Paolo Bruzzi, Maria Teresa Van Lint, Andrea Bacigalupo.   

Abstract

At the bone marrow transplantation center of the San Martino Hospital (Genoa), we observed an increase in the rate of patients with positive Platelia Aspergillus (PA; Bio-Rad) test results, from 10% (38 of 386 patients) in the period from January 1999 through January 2003 to 36% (21 of 59 patients) in the period from February 2003 through May 2003. Positivity was significantly (P<.001) associated with the administration of piperacillin-tazobactam (PT) (17 [74%] of 23 patients who received PT had positive results vs. 4 [11%] of 36 who did not receive PT). Multivariate analysis found administration of PT ( chi 2=34.7; P<.001) and underlying disease ( chi 2=21.14; P<.001) to be associated with PA positivity. Of 15 PT batches tested, 12 had positive PA test results.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999640     DOI: 10.1086/382224

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  53 in total

Review 1.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

Review 2.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  False positivity for Aspergillus antigenemia with amoxicillin-clavulonic acid.

Authors:  Gokhan Metan; Mine Durusu; Omrum Uzun
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

4.  Galactomannan in piperacillin-tazobactam: how much and to what extent?

Authors:  Marco Machetti; Elisa Furfaro; Claudio Viscoli
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Use of real-time PCR to process the first galactomannan-positive serum sample in diagnosing invasive aspergillosis.

Authors:  Laurence Millon; Renaud Piarroux; Eric Deconinck; Claude-Eric Bulabois; Frédéric Grenouillet; Pierre Rohrlich; Jean-Marc Costa; Stéphane Bretagne
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

6.  Intravenous PLASMA-LYTE as a major cause of false-positive results of platelia Aspergillus test for galactomannan detection in serum.

Authors:  Zdenek Racil; Iva Kocmanova; Martina Lengerova; Jana Winterova; Jiri Mayer
Journal:  J Clin Microbiol       Date:  2007-08-01       Impact factor: 5.948

7.  Well-characterized monoclonal antibodies against cell wall antigen of Aspergillus species improve immunoassay specificity and sensitivity.

Authors:  Wei Hao; Yu-Xian Pan; Yan-Qing Ding; Sha Xiao; Kai Yin; Ya-Di Wang; Li-Wen Qiu; Qing-Lin Zhang; Patrick C Y Woo; Susanna K P Lau; Kwok-Yung Yuen; Xiao-Yan Che
Journal:  Clin Vaccine Immunol       Date:  2007-11-21

8.  Beta-D-glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised critically ill patients with symptoms of respiratory infection: an autopsy-based study.

Authors:  Greet De Vlieger; Katrien Lagrou; Johan Maertens; Eric Verbeken; Wouter Meersseman; Eric Van Wijngaerden
Journal:  J Clin Microbiol       Date:  2011-08-31       Impact factor: 5.948

9.  Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments.

Authors:  Emmanuelle Bart-Delabesse; Maria Basile; Ahmad Al Jijakli; Didier Souville; Frédérick Gay; Bruno Philippe; Philippe Bossi; Martin Danis; Jean-Paul Vernant; Annick Datry
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 10.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.